KG acted as Greek legal counsel to Medtronic in the global spin-off, enabling the successful carve-out and transfer of Medtronic’s diabetes business to the newly established MiniMed Group.
The transaction spanned over a period of eighteen months and culminated in MiniMed’s Nasdaq IPO—one of the largest medtech listings to date—drawing strong investor demand and achieving significant oversubscription. A dedicated multidisciplinary KG team advised across corporate, employment, regulatory and pharmaceutical matters, and supported the transition with the key commercial agreements required for a seamless separation. Baker McKenzie Sydney and London offices acted as global legal counsel.
The KG team was led by Partners Konstantinos Vouterakos and Vasileios Douzenis, supported by Associate Katerina Vogka. Labour & Employment matters were handled by Counsel Kelly Papadaki and Senior Associate Ioanna Chanoumi. Pharma law advice was provided by Partner Irene Kyriakides and Associate Aithra Antoniadou. Competition and FDI aspects were led by Partner Victoria Mertikopoulou, assisted by Associate Ifigeneia Argyri.
We are proud to have contributed to this long and complex cross-border transaction and look forward to continuing to support our clients in navigating large-scale multinational deals.
Congratulations to all teams on their punctual collaboration and persevering commitment to bring this transaction to the finish line.